Roche Holding AG's diagnostics division and U.S.-based Mayo Clinic have agreed to investigate offering drug selection and dosing information for the treatment of psychiatric patients.Technorati Tags: Roche, Mayo Clinic, AmpliChip, CYP450
The companies' first step is to co-develop a prototype IT-enabled system that will refine Mayo Clinic's extensive psychiatric and pharmacogenomic clinical expertise, Roche said in a statement on Tuesday.
The prototype system will offer drug selection and dosing information for a broad range of psychotropic therapeutics based on patient test results from Roche's AmpliChip CYP450 test.
I'm Dr. Joshua Schwimmer, a nephrologist and internal medicine physician in New York City. • Kidney Notes was the first active nephrology blog. (Trivia: Kidney Notes is so old that the National Library of Medicine still uses it as an example of how to formally cite blogs.) • Professionally, you can find me at Kidney.nyc. • Kidney Notes is for educational purposes only, not medical advice. Consult qualified health care professionals. See disclaimer.
Tuesday, October 11, 2005
Roche and Mayo Clinic Collaborate on AmpliChip CYP450 Drug Selection Tool
A previous posting on the AmpliChip CYP450 test for individual variability in drug metabolism (one of Forbes' "top ten medical tests you need," oddly) is here. Via Reuters: